CERUS CORP (CERS) Fundamental Analysis & Valuation

NASDAQ:CERS • US1570851014

Current stock price

1.78 USD
-0.05 (-2.73%)
At close:
1.77 USD
-0.01 (-0.56%)
After Hours:

This CERS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. CERS Profitability Analysis

1.1 Basic Checks

  • CERS had negative earnings in the past year.
  • CERS had a positive operating cash flow in the past year.
  • CERS had negative earnings in each of the past 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: CERS reported negative operating cash flow in multiple years.
CERS Yearly Net Income VS EBIT VS OCF VS FCFCERS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M -60M

1.2 Ratios

  • CERS has a better Return On Assets (-7.04%) than 66.67% of its industry peers.
  • CERS has a Return On Equity (-24.33%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -7.04%
ROE -24.33%
ROIC N/A
ROA(3y)-12.14%
ROA(5y)-15.79%
ROE(3y)-44.26%
ROE(5y)-52.08%
ROIC(3y)N/A
ROIC(5y)N/A
CERS Yearly ROA, ROE, ROICCERS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

  • With a decent Gross Margin value of 59.86%, CERS is doing good in the industry, outperforming 61.90% of the companies in the same industry.
  • In the last couple of years the Gross Margin of CERS has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for CERS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 59.86%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.2%
GM growth 5Y-1.33%
CERS Yearly Profit, Operating, Gross MarginsCERS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. CERS Health Analysis

2.1 Basic Checks

  • CERS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, CERS has more shares outstanding
  • CERS has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for CERS has been reduced compared to a year ago.
CERS Yearly Shares OutstandingCERS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
CERS Yearly Total Debt VS Total AssetsCERS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

2.2 Solvency

  • CERS has an Altman-Z score of -4.16. This is a bad value and indicates that CERS is not financially healthy and even has some risk of bankruptcy.
  • CERS's Altman-Z score of -4.16 is on the low side compared to the rest of the industry. CERS is outperformed by 68.25% of its industry peers.
  • CERS has a debt to FCF ratio of 75.71. This is a negative value and a sign of low solvency as CERS would need 75.71 years to pay back of all of its debts.
  • CERS has a better Debt to FCF ratio (75.71) than 68.25% of its industry peers.
  • CERS has a Debt/Equity ratio of 0.63. This is a neutral value indicating CERS is somewhat dependend on debt financing.
  • CERS's Debt to Equity ratio of 0.63 is on the low side compared to the rest of the industry. CERS is outperformed by 63.49% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF 75.71
Altman-Z -4.16
ROIC/WACCN/A
WACC11.15%
CERS Yearly LT Debt VS Equity VS FCFCERS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 1.73 indicates that CERS should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.73, CERS is doing worse than 67.72% of the companies in the same industry.
  • CERS has a Quick Ratio of 1.17. This is a normal value and indicates that CERS is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Quick ratio value of 1.17, CERS is not doing good in the industry: 69.84% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.73
Quick Ratio 1.17
CERS Yearly Current Assets VS Current LiabilitesCERS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. CERS Growth Analysis

3.1 Past

  • CERS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.27%, which is quite impressive.
  • Looking at the last year, CERS shows a quite strong growth in Revenue. The Revenue has grown by 16.13% in the last year.
  • Measured over the past years, CERS shows a quite strong growth in Revenue. The Revenue has been growing by 15.41% on average per year.
EPS 1Y (TTM)27.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)16.13%
Revenue growth 3Y7.48%
Revenue growth 5Y15.41%
Sales Q2Q%13.66%

3.2 Future

  • Based on estimates for the next years, CERS will show a very strong growth in Earnings Per Share. The EPS will grow by 45.86% on average per year.
  • CERS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.77% yearly.
EPS Next Y49%
EPS Next 2Y45.86%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year9.45%
Revenue Next 2Y9.15%
Revenue Next 3Y8.77%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CERS Yearly Revenue VS EstimatesCERS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M 200M 250M
CERS Yearly EPS VS EstimatesCERS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.2 -0.4 -0.6

More info and screens

Find the best growth stocksShow best growing peers

2

4. CERS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CERS. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CERS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CERS Price Earnings VS Forward Price EarningsCERS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

  • CERS's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. CERS is cheaper than 68.25% of the companies in the same industry.
Industry RankSector Rank
P/FCF 308.72
EV/EBITDA N/A
CERS Per share dataCERS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CERS's earnings are expected to grow with 45.86% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y45.86%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CERS Dividend Analysis

5.1 Amount

  • CERS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CERS Fundamentals: All Metrics, Ratios and Statistics

CERUS CORP

NASDAQ:CERS (3/27/2026, 8:05:47 PM)

After market: 1.77 -0.01 (-0.56%)

1.78

-0.05 (-2.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-02
Earnings (Next)04-29
Inst Owners73.28%
Inst Owner Change2.12%
Ins Owners2.79%
Ins Owner Change-3.2%
Market Cap342.06M
Revenue(TTM)233.80M
Net Income(TTM)-15.63M
Analysts80
Price Target5.1 (186.52%)
Short Float %4.2%
Short Ratio4.58
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)34.64%
Min EPS beat(2)-30.72%
Max EPS beat(2)100%
EPS beat(4)2
Avg EPS beat(4)17.24%
Min EPS beat(4)-30.72%
Max EPS beat(4)100%
EPS beat(8)5
Avg EPS beat(8)17.63%
EPS beat(12)7
Avg EPS beat(12)18.46%
EPS beat(16)10
Avg EPS beat(16)13.56%
Revenue beat(2)0
Avg Revenue beat(2)-3.77%
Min Revenue beat(2)-5.03%
Max Revenue beat(2)-2.51%
Revenue beat(4)0
Avg Revenue beat(4)-6.89%
Min Revenue beat(4)-14.57%
Max Revenue beat(4)-2.51%
Revenue beat(8)1
Avg Revenue beat(8)-5.4%
Revenue beat(12)1
Avg Revenue beat(12)-7.05%
Revenue beat(16)5
Avg Revenue beat(16)-3.28%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-33.33%
EPS NQ rev (3m)-33.33%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-3.04%
Revenue NQ rev (3m)-3.04%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)-0.04%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.46
P/FCF 308.72
P/OCF 70.72
P/B 5.33
P/tB 5.44
EV/EBITDA N/A
EPS(TTM)-0.08
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)0.01
FCFY0.32%
OCF(TTM)0.03
OCFY1.41%
SpS1.22
BVpS0.33
TBVpS0.33
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -7.04%
ROE -24.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 59.86%
FCFM 0.47%
ROA(3y)-12.14%
ROA(5y)-15.79%
ROE(3y)-44.26%
ROE(5y)-52.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.2%
GM growth 5Y-1.33%
F-Score5
Asset Turnover1.05
Health
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF 75.71
Debt/EBITDA N/A
Cap/Depr 261.5%
Cap/Sales 1.59%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.73
Quick Ratio 1.17
Altman-Z -4.16
F-Score5
WACC11.15%
ROIC/WACCN/A
Cap/Depr(3y)197.11%
Cap/Depr(5y)137.46%
Cap/Sales(3y)1.82%
Cap/Sales(5y)1.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y49%
EPS Next 2Y45.86%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)16.13%
Revenue growth 3Y7.48%
Revenue growth 5Y15.41%
Sales Q2Q%13.66%
Revenue Next Year9.45%
Revenue Next 2Y9.15%
Revenue Next 3Y8.77%
Revenue Next 5YN/A
EBIT growth 1Y38.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year285.75%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-57.42%
OCF growth 3YN/A
OCF growth 5YN/A

CERUS CORP / CERS Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for CERUS CORP?

ChartMill assigns a fundamental rating of 3 / 10 to CERS.


Can you provide the valuation status for CERUS CORP?

ChartMill assigns a valuation rating of 2 / 10 to CERUS CORP (CERS). This can be considered as Overvalued.


How profitable is CERUS CORP (CERS) stock?

CERUS CORP (CERS) has a profitability rating of 2 / 10.


What is the financial health of CERUS CORP (CERS) stock?

The financial health rating of CERUS CORP (CERS) is 3 / 10.


Can you provide the expected EPS growth for CERS stock?

The Earnings per Share (EPS) of CERUS CORP (CERS) is expected to grow by 49% in the next year.